Oruka Therapeutics Inc. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Vanguard Value Index Fund ETF trades at $221.56 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 51.7× Oruka Therapeutics Inc. Common Stock's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| ORKA | VTV | |
|---|---|---|
Market Cap | $5.08B | $262.40B |
Volume | 685,276 | 2,800,630 |
Sector | Health | — |
52-Week High | $113.08 | $227.51 |
52-Week Low | $26.19 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $4.21B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VTV trades at $220.67, down 0.34% on the day, with a bullish technical signal supported by moving averages but mixed oscillators. The ETF shows strong institutional interest with recent acquisitions by QRG Capital Management and Blue Edge Capital. Recent news highlights VTV's 2.3% dividend yield and value-focused strategy outperforming growth counterparts in 2026, with value stocks gaining traction amid market rotation away from tech concentration.
VTV presents a compelling value proposition with low 0.03% fees and income appeal, though long-term performance trails the S&P 500. Key risks include sustained growth stock dominance and interest rate sensitivity. The ETF's diversification across value stocks positions it well for investors seeking stability amid market uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →